Skip to main content
. 2022 Aug 20;8:95. doi: 10.1038/s41523-022-00468-0

Fig. 5. Therapeutic approaches in metastatic TNBC (red: current approaches, Blue: future directions).

Fig. 5

ADC antibody drug conjugate; PARPi: poly-ADP ribose polymerase inhibitors; HRD homologous recombination deficiency; AR androgen receptors. Figure includes modified templates from Servier Medical Art (smart.servier.com).